- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Post-transplant cytomegalovirus (CMV)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 932MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 158MB)
Maribavir – November 2023
Maribavir: Tablet 200 mg; Livtencity®
Last updated
15 March 2024